Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Genmab Achieves $30M Janssen Milestone | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Genmab Achieves $30M Janssen Milestone

Triggered by first commercial sale of DARZALEX in Europe

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Genmab has achieved $30 million milestone in its DARZALEX (daratumumab) collaboration with Janssen Biotech, triggered by the first commercial sale of the drug in Europe.
 
The European Commission recently granted a conditional marketing authorization for first-in-class CD38 immunotherapy DARZALEX as monotherapy for the treatment of relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor (PI) and an immunomodulatory agent and who have demonstrated disease progression.
 
“We continue to be impressed by the rapid speed with which our collaboration partner, Janssen, has been able to develop and launch DARZALEX in Europe,” said Jan van de Winkel, Ph.D., chief executive officer of Genmab.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics